Knight study on multiple myeloma supports new standard of treatment

A new study, published in the New England Journal of Medicine, found that 63 percent of multiple myeloma patients have a reduced risk of disease progression or death if treated with lenalidomide (Revlimid®) following a stem cell transplant. The study was co-authored by Richard Mariarz, MD, medical director of the Adult Stem Cell Transplantation Program & Center for Hematologic Malignancies at the Knight Cancer Institute.

Read the OHSU News Release to learn more.